查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1855753

口服避孕藥市場依產品類型、劑型、劑量強度、品牌及通路分類－2025-2032年全球預測

Oral Contraceptive Pills Market by Product Type, Formulation, Dosage Strength, Brand, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服避孕藥市場規模將達到 317.7 億美元，複合年成長率為 7.08%。

主要市場統計數據
基準年 2024 183.6億美元
預計年份：2025年 196.6億美元
預測年份：2032年 317.7億美元
複合年成長率 (%) 7.08%

簡要概述了目前口服避孕藥的現狀，重點闡述了影響相關人員決策的臨床、監管和獲取途徑等方面的動態。

口服避孕藥仍然是全球生殖健康策略的基石，其在計劃生育、臨床護理和公共衛生政策中的作用也在不斷演變。醫療服務提供者、付款方和生產商所處的環境受到監管重點變化、遠距遠端醫療服務擴展以及患者對安全性、便利性和成本透明度的期望不斷提高的影響。因此，對於那些必須在臨床療效與供應鏈和商業性現實之間取得平衡的利害關係人相關人員，了解影響藥物配製、依從性和可及性的動態至關重要。

數位醫療的擴張、監管格局的調整以及藥物配方的演變，正在如何再形成口服避孕藥市場的獲取途徑、用藥行為和醫療服務提供者的策略？

口服避孕藥市場正經歷一場變革性的轉變，這場變革正在改變產品的研發、配製、分銷以及使用者認知。數位醫療的進步加速了遠端醫療諮詢和線上藥局的發展，使配製藥物更加便捷，但也帶來了新的合規性和檢驗的挑戰。與此同時，政策舉措——例如某些地區的非處方藥銷售以及另一些地區擴大藥劑師的配製權限——正在改變傳統的准入把關者，並迫使製造商重新思考包裝、標籤和患者支持服務。

分析近期美國關稅如何促使口服避孕藥生態系進行供應鏈重組、來源多元化以及籌資策略調整。

美國近期推出的貿易執法措施對口服避孕藥供應鏈的多個環節產生了累積影響。更高的進口關稅和對上游供應商更嚴格的審查可能會改變原料藥採購和成品藥生產的成本核算，促使生產商重新評估籌資策略、生產佈局和庫存政策。因此，各公司正在考慮近岸外包、雙重採購和簽訂長期供應商協議，以降低關稅波動帶來的風險，並確保供應的連續性。

將產品類型、配方差異、劑量策略、品牌定位和分銷管道與競爭和業務重點聯繫起來的詳細細分資訊。

關鍵的市場區隔考量揭示了產品屬性、配方、給藥策略、品牌定位和通路結構如何相互作用，從而決定競爭機會和風險。按產品類型分類，口服避孕藥和僅含孕激素的避孕藥之間的市場差異導致了不同的藥物組合模式、耐受性特徵和目標患者群體，這些差異會影響行銷、醫學教育和配方設計。按劑型分類，雙相、單相和三相製劑之間的差異會影響出血模式、週期控制預期以及臨床醫生和患者的教育訊息。

針對美洲、歐洲、中東和非洲以及亞太地區的區域戰略考量，將決定監管重點、分銷管道和生產​​選擇。

區域動態為在不同地理叢集運作的相關人員創造了不同的策略要務。在美洲，法律規範、支付方構成和遠端醫療普及率影響著零售藥局、醫院採購和線上銷售之間的平衡，進而影響著特定的市場進入模式和報銷考量。相較之下，歐洲、中東和非洲在監管要求和醫療基礎設施方面存在顯著差異，因此需要採取適應性強的許可策略、差異化的臨床證據包裝以及經銷夥伴，以反映當地的採購規範和公共採購週期。

競爭情報揭示了配方創新、供應韌性、策略夥伴關係和生命週期管理如何驅動口服避孕藥領域的領先地位。

口服避孕藥領域的企業競爭動態取決於配方創新、供應鏈韌性、商業性可行性以及向臨床醫生和支付方展現差異化價值的能力。典型的策略措施包括投資以病人為中心的資訊和依從性服務、確保關鍵中間體的長期供應協議，以及優先利用監管管道加速市場進入。此外，生命週期管理策略，例如配方改進、包裝重新設計和適應症擴展，也常被用於延長產品生命週期並維繫配方研發人員的忠誠度。

為行業領導者提供可操作的策略重點，以協調證據生成、採購韌性、數位化參與和相關人員倡導，從而實現持續的市場優勢。

為了保持競爭優勢，產業領導者應採取多管齊下的策略，協調臨床證據的產生、供應鏈的彈性和通路商業化。首先，將可靠的真實世界依從性測試和上市後監測納入產品系列，有助於加強與支付方的談判，並為臨床通訊傳遞提供依據。其次，透過合格的雙重採購和選擇性近岸外包，實現原料藥和成品生產的多元化，可以在保持成本競爭力的同時，降低受貿易政策變化和物流中斷的影響。

一個嚴謹的混合方法研究框架，結合了相關人員訪談、監管和臨床文獻整合以及交叉檢驗的情境分析，以得出可操作的結論。

本分析所依據的研究結合了定性和定量方法，旨在驗證趨勢、整合不同觀點，並為決策者提供切實可行的建議。主要研究包括對臨床醫生、採購負責人、藥屋主任和行業高管進行結構化檢驗，以獲取有關配藥行為、籌資策略和分銷挑戰的第一手資料。次要研究則利用監管文件、臨床指南更新、政策公告和開放原始碼文獻，揭示了藥物取得和製劑偏好的變化。

將監管變革、供應鏈韌性、配方創新和以患者為中心的交付方式有效整合，是該領域未來成功的核心驅動力。

摘要：口服避孕藥市場正處於曲折點，不斷變化的監管環境、數位化管道和供應鏈動態正在共同重塑產品的研發、供應和使用方式。積極主動地將臨床證據的生成與適應性籌資策略和管道專屬的商業化相結合的相關人員，將更有能力滿足不斷變化的患者需求並降低風險。過渡性政策措施和貿易發展凸顯了靈活採購和長期供應商關係的重要性，而製劑差異化和病患支援服務則為企業提供了明確的競爭優勢途徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 哺乳期和產後母親使用僅含孕激素的口服避孕藥的比例增加
  • 人們越來越傾向於選擇低劑量複方口服避孕藥，以最大限度地減少副作用並提高用藥偏好。
  • 市場對具有臨床驗證的健康益處（除避孕功效外）的口服避孕藥的需求激增
  • 擴大線上避孕藥配製和家庭配送遠端醫療服務的整合
  • 無激素、短週期（24/4）和長週期避孕藥越來越受歡迎
  • 數位生育追蹤應用程式的出現，結合個人化口服避孕藥用於週期管理。
  • 隨著主要品牌口服避孕藥專利到期，非專利藥的市場滲透率不斷提高。
  • 消費者偏好轉向環保包裝與永續採購

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的口服避孕藥市場

  • 複方口服避孕藥
  • 僅含黃體素的避孕藥

第9章 依劑型分類的口服避孕藥市場

  • 雙相
  • 單相
  • 三相

第10章 以劑量強度分類的口服避孕藥市場

  • 高劑量
  • 低劑量

第11章 口服避孕藥品牌市場

  • 品牌
  • 非專利的

第12章 口服避孕藥市場（依通路分類）

  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 線上平台
  • 零售藥房

第13章 各地區口服避孕藥市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 口服避孕藥市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國口服避孕藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Viatris Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Gedeon Richter Plc
    • Lupin Limited
    • Dr. Reddy's Laboratories Ltd.
    • Sandoz International GmbH
Product Code: MRR-4676B64E6B2E

The Oral Contraceptive Pills Market is projected to grow by USD 31.77 billion at a CAGR of 7.08% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.36 billion
Estimated Year [2025] USD 19.66 billion
Forecast Year [2032] USD 31.77 billion
CAGR (%) 7.08%

A succinct orienting overview of the contemporary oral contraceptive pills landscape highlighting clinical, regulatory, and access dynamics shaping stakeholder decisions

Oral contraceptive pills remain a cornerstone of reproductive health strategies globally, and their role in family planning, clinical care, and public health policy continues to evolve. Providers, payers, and manufacturers operate in an environment shaped by shifting regulatory priorities, expanding telehealth provision, and changing patient expectations for safety, convenience, and cost transparency. Consequently, understanding the dynamics that influence prescribing practices, adherence, and accessibility is essential for stakeholders who must balance clinical efficacy with supply chain and commercial realities.

In addition, the social and political context surrounding contraception influences demand patterns, formulary decisions, and public sector procurement strategies. Emerging digital health pathways are reshaping how patients access prescriptions and adhere to recommended regimens, while formulation innovation and lifecycle management of both branded and generic products are redefining competitive dynamics. Therefore, an actionable introduction to this landscape must acknowledge the interplay between clinical guidance, regulatory frameworks, and market channels, and set the stage for deeper analysis that follows in subsequent sections.

How digital health expansion, regulatory rebalancing, and formulation evolution are reshaping access, prescribing behavior, and supplier strategies in the oral contraceptive market

The oral contraceptive market is experiencing transformative shifts that are altering how products are developed, prescribed, distributed, and perceived by users. Advances in digital health have accelerated telemedicine consultations and online pharmacy fulfillment, enabling more rapid access to prescriptions while also introducing new compliance and verification challenges. At the same time, policy movements toward over-the-counter availability in some jurisdictions and expanded pharmacist prescribing authority in others are changing the traditional gatekeepers of access and prompting manufacturers to reconsider packaging, labeling, and patient support services.

Moreover, clinical and formulation trends are prompting differentiated product strategies. Patient-centric formulations and lower-hormone options are gaining attention as providers seek to balance efficacy with tolerability, and there is renewed focus on real-world adherence data to inform guideline updates and payer decisions. Parallel to these clinical shifts are supply-side transformations: contract manufacturing optimization, API sourcing diversification, and vertical integration strategies are being deployed to mitigate disruptions. Finally, increased competition from generic manufacturers and a heightened emphasis on value-based procurement are driving innovation in patient support programs, digital adherence tools, and evidence generation to sustain brand differentiation.

Analyzing how recent United States tariff measures are prompting supply chain realignment, sourcing diversification, and procurement strategy adjustments across the oral contraceptive ecosystem

Recent trade policy measures introduced in the United States have created a cumulative impact across multiple facets of the oral contraceptive supply chain. Increased import tariffs and heightened scrutiny of upstream suppliers can alter the cost calculus for active pharmaceutical ingredient procurement and finished-dose manufacturing, prompting manufacturers to reevaluate sourcing strategies, manufacturing footprints, and inventory policies. As a result, companies are increasingly considering nearshoring, dual-sourcing, and long-term supplier contracts to reduce exposure to tariff volatility and ensure continuity of supply.

At the clinical procurement level, hospitals, clinics, and pharmacies are responding to these shifts by reassessing purchasing agreements and inventory buffers. Transitional effects include renegotiation of tender terms and closer collaboration between procurement and regulatory affairs teams to anticipate customs clearance complexities. In response to potential cost pressures, some manufacturers are enhancing operational efficiency through process improvements and scale consolidation, while others pursue strategic partnerships to secure critical intermediates. Importantly, these structural adjustments are unfolding alongside policy and judicial reviews that may change the long-term tariff landscape, so stakeholders should plan for both immediate operational contingencies and sustained strategic realignments.

In-depth segmentation intelligence linking product type, formulation nuances, dosage strategies, brand positioning, and distribution channels to competitive and operational priorities

Key segmentation insights reveal how product characteristics, formulation design, dosing strategies, brand positioning, and channel structures interact to determine competitive opportunity and risk. Based on Product Type, the market distinctions between combined oral contraceptives and progestin-only pills drive differences in prescribing patterns, tolerability profiles, and target patient cohorts, which in turn influence marketing, medical education, and formulary approaches. Based on Formulation, the differences among biphasic, monophasic, and triphasic designs affect bleeding patterns, cycle control expectations, and the messaging required for clinician and patient education.

Furthermore, based on Dosage Strength, the strategic differentiation between high dose and low dose pills has implications for adverse event profiles, adherence considerations, and patient preference segmentation. Based on Brand, the tension between branded and generic offerings shapes lifecycle management, reimbursement strategies, and investment in patient support or real-world evidence generation. Finally, based on Distribution Channel, the structure that encompasses hospital pharmacy, online platforms, and retail pharmacy-with the hospital pharmacy further studied across private hospital and public hospital environments-determines procurement models, reimbursement flows, inventory practices, and the configuration of patient access programs. Integrating these segmentation lenses enables more precise commercial planning, tailored messaging for clinicians and patients, and alignment of manufacturing volumes with channel-led demand.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory priorities, distribution pathways, and manufacturing choices

Regional dynamics create distinct strategic imperatives for stakeholders operating across different geographic clusters. In the Americas, regulatory frameworks, payer mixes, and telehealth adoption rates influence the balance between retail pharmacy, hospital procurement, and online distribution, driving specific go-to-market models and reimbursement considerations. In contrast, the Europe, Middle East & Africa grouping exhibits wide heterogeneity in regulatory requirements and healthcare infrastructure, which necessitates adaptive licensing strategies, differentiated clinical evidence packages, and tailored distribution partnerships that reflect local procurement norms and public-sector procurement cycles.

Meanwhile, the Asia-Pacific region presents a diverse set of market conditions where rapid digital adoption intersects with variable regulatory timelines and manufacturing capabilities. In many jurisdictions within this region, strong local manufacturing ecosystems and evolving intellectual property enforcement standards affect decisions about local production versus export orientation. Taken together, these regional variations require companies to deploy nuanced market-entry strategies, prioritize regulatory and commercial investments by country or cluster, and synchronize supply chain and distribution models with regional payer and provider behaviors.

Competitive intelligence revealing how formulation innovation, supply resilience, strategic partnerships, and lifecycle management define leadership in the oral contraceptive category

Competitive dynamics among companies active in the oral contraceptive category are defined by a combination of innovation in formulations, supply chain resilience, commercial execution, and the ability to demonstrate differentiated value to clinicians and payers. Leading strategic approaches include investing in patient-centric information and adherence services, securing long-term supply agreements for key intermediates, and prioritizing regulatory pathways that accelerate market access. In addition, lifecycle management tactics such as incremental formulation changes, packaging redesigns, and expanded indications are commonly used to extend product relevance and maintain prescriber loyalty.

Partnerships and alliances, including those with contract manufacturers, digital health platforms, and specialty distributors, are increasingly central to delivering end-to-end solutions that address both clinical adherence and convenience. Meanwhile, companies focusing on generic entry leverage scale manufacturing and cost optimization to compete on price, while larger innovators may emphasize clinical evidence, patient support infrastructure, and brand trust to preserve premium positioning. Across these strategies, firms that align R&D priorities with real-world outcomes and that coordinate effectively across regulatory, supply chain, and commercial functions are better positioned to navigate evolving policy and distribution landscapes.

Actionable strategic priorities for industry leaders to synchronize evidence generation, sourcing resilience, digital engagement, and stakeholder advocacy for sustained market advantage

Industry leaders should adopt a multi-dimensional strategy that harmonizes clinical evidence generation, supply chain flexibility, and channel-specific commercialization to sustain competitive advantage. First, integrating robust real-world adherence studies and post-marketing surveillance into product portfolios will strengthen payer negotiations and inform clinical messaging. Second, diversifying API and finished-dose manufacturing through qualified dual sourcing and selective nearshoring will reduce exposure to trade policy shifts and logistical disruptions while maintaining cost competitiveness.

Moreover, companies should accelerate their digital engagement strategies by embedding telehealth-compatible prescribing support, personalized adherence tools, and seamless e-commerce fulfillment to meet growing patient expectations. Concurrently, active engagement with policymakers, payers, and professional societies will help shape favorable prescribing frameworks and pharmacist scope-of-practice expansions. Finally, leaders should consider targeted investments in brand-differentiating services such as nurse-led counseling, patient education platforms, and value-based contracting pilots to demonstrate outcomes and foster long-term trust with prescribers and patients.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and clinical literature synthesis, and cross-validated scenario analysis to underpin actionable conclusions

The research underpinning this analysis relies on a combination of qualitative and quantitative approaches designed to validate trends, triangulate perspectives, and identify practical implications for decision makers. Primary research included structured interviews with clinicians, procurement officers, pharmacy directors, and industry executives to capture firsthand insights on prescribing behaviors, procurement strategies, and distribution challenges. Secondary research drew on regulatory filings, clinical guideline updates, policy announcements, and open-source literature to contextualize shifts in access and formulation preferences.

Data synthesis employed a cross-validation framework that reconciled stakeholder interviews with documented regulatory changes and supply chain developments, while scenario analysis was used to explore the implications of policy and trade variations. Limitations of the methodology include the inherent lag between policy announcements and observable market responses, and the variability of clinical and procurement practices across jurisdictions. Nonetheless, the combined methodological approach provides a robust foundation for strategic recommendations, and the findings were further reviewed by domain experts to ensure relevance and practical applicability.

Concluding synthesis that connects regulatory change, supply resilience, formulation innovation, and patient-centric delivery as the core drivers of future success in the category

In summary, the oral contraceptive landscape is at an inflection point where regulatory shifts, digital access pathways, and supply chain dynamics converge to reshape how products are developed, delivered, and used. Stakeholders who proactively align clinical evidence generation with adaptive sourcing strategies and channel-specific commercialization will be better equipped to meet evolving patient needs and mitigate risk. Transitional policy measures and trade developments underscore the importance of agile procurement and long-term supplier relationships, while formulation differentiation and patient support services offer clear avenues for competitive advantage.

Looking ahead, sustained success will depend on the ability to integrate cross-functional insights into coherent strategies that address both near-term operational challenges and longer-term clinical and market trends. By prioritizing resilience, evidence, and patient-centric delivery models, organizations can navigate uncertainty and harness emerging opportunities to improve access and outcomes for patients who rely on oral contraceptive pills.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increased adoption of progestin-only oral contraceptive pills among breastfeeding and postpartum mothers
  • 5.2. Growing preference for low-dose combined oral contraceptives to minimize side effects and enhance adherence
  • 5.3. Surge in demand for oral contraceptives with clinically proven non-contraceptive health benefits
  • 5.4. Expanding telehealth service integration for online prescription and home delivery of contraceptive pills
  • 5.5. Rising popularity of 24/4 and extended-cycle pill regimens offering fewer hormone-free intervals
  • 5.6. Emergence of digital fertility-tracking apps paired with oral contraceptives for personalized cycle management
  • 5.7. Increasing market penetration of generic oral contraceptives following patent expirations of leading brands
  • 5.8. Shifts in consumer preference toward eco-friendly packaging and sustainable sourcing of contraceptive pills

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Contraceptive Pills Market, by Product Type

  • 8.1. Combined Oral Contraceptives
  • 8.2. Progestin-Only Pills

9. Oral Contraceptive Pills Market, by Formulation

  • 9.1. Biphasic
  • 9.2. Monophasic
  • 9.3. Triphasic

10. Oral Contraceptive Pills Market, by Dosage Strength

  • 10.1. High Dose
  • 10.2. Low Dose

11. Oral Contraceptive Pills Market, by Brand

  • 11.1. Branded
  • 11.2. Generic

12. Oral Contraceptive Pills Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Private Hospital
    • 12.1.2. Public Hospital
  • 12.2. Online Platforms
  • 12.3. Retail Pharmacy

13. Oral Contraceptive Pills Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Contraceptive Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Contraceptive Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Bayer AG
    • 16.3.2. Teva Pharmaceutical Industries Ltd.
    • 16.3.3. Pfizer Inc.
    • 16.3.4. Merck & Co., Inc.
    • 16.3.5. Viatris Inc.
    • 16.3.6. Sun Pharmaceutical Industries Ltd.
    • 16.3.7. Gedeon Richter Plc
    • 16.3.8. Lupin Limited
    • 16.3.9. Dr. Reddy's Laboratories Ltd.
    • 16.3.10. Sandoz International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ORAL CONTRACEPTIVE PILLS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 109. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 120. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 144. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 178. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 180. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 182. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 186. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 187. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 192. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 193. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 194. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 195. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 196. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 197. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 200. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 222. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 223. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 224. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 225. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 226. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 227. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 230. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 231. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 236. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 237. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 238. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 239. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 240. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 241. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 244. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 259. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 264. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 265. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 266. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 267. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 268. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 269. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 272. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 273. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 278. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 279. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 280. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 281. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 282. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 283. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 286. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 287. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 292. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 293. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 294. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 295. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 296. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 297. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 298. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 299. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 300. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 307. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 308. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 309. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)
  • TABLE 310. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025-2032 (USD MILLION)
  • TABLE 311. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
  • TABLE 314. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2032 (USD MILLION)
  • TABLE 315. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 318. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 319. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
  • TABLE 320. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2032 (USD MILLION)
  • TABLE 321. CANADA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2024 (USD MILLION)

T